In our past clinical studies [3, 12, 45], we consistently observed a statistically significant decrease in plasma BDNF levels at 6 and 12 weeks after breast cancer patients were treated with ADR and cyclophosphamide (ADR-CYP). This evidence concerns the gene PPIG and breast carcinoma.